Related Experiment Video
Updated: Aug 11, 2026
A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
Published on: February 28, 2012
Reduction in ventricular tachyarrhythmias with statins in the Multicenter Automatic Defibrillator Implantation Trial
Anant K Vyas1, Hongsheng Guo, Arthur J Moss
1Heart Research Follow-up Program of the Cardiology Unit of the Department of Medicine, University of Rochester Medical Center, Rochester, New York 14642, USA. anantvyas@hotmail.com
Insights
Statin use in patients with implantable cardioverter-defibrillators (ICDs) significantly reduced the risk of ventricular tachycardia/ventricular fibrillation (VT/VF) or cardiac death. These findings suggest statins possess anti-arrhythmic properties.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Emerging evidence suggests lipid-lowering drugs may exhibit anti-arrhythmic properties in patients with coronary artery disease.
- The potential anti-arrhythmic effects of statins warrant further investigation, particularly in patient populations at high risk for ventricular arrhythmias.
Purpose of the Study:
- To investigate the association between statin use and the incidence of appropriate implantable cardioverter-defibrillator (ICD) therapy for ventricular tachycardia/ventricular fibrillation (VT/VF).
- To explore the potential anti-arrhythmic effects of statins in patients with an ICD.
Main Methods:
- Analysis of data from the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II, including 654 patients with ICDs.
- Categorization of patients based on the percentage of days statin therapy was administered during follow-up.
- Utilized Kaplan-Meier analysis and time-dependent proportional hazards regression to assess the impact of statin use on VT/VF and cardiac death endpoints.
Main Results:
- Patients with high statin usage (≥90% of days) demonstrated a significantly reduced cumulative rate of ICD therapy for VT/VF or cardiac death (p=0.01).
- Time-dependent analysis revealed a hazard ratio of 0.65 for VT/VF or cardiac death (p<0.01) and 0.72 for VT/VF (p=0.046) in statin users compared to non-users, after adjusting for covariates.
- These results indicate a significant protective effect of statin therapy against life-threatening ventricular arrhythmias.
Conclusions:
- Statin use in patients with an ICD is associated with a significant reduction in the risk of cardiac death or VT/VF.
- The observed reduction in VT/VF episodes suggests that statins possess inherent anti-arrhythmic properties.
- These findings support the consideration of statins as a potential adjunctive therapy for managing ventricular arrhythmias in high-risk patients.
Objectives:
We evaluated whether statins have anti-arrhythmic effects by exploring the association of statin use with appropriate implantable cardioverter-defibrillator (ICD) therapy for ventricular tachycardia/ventricular fibrillation (VT/VF) in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II.
Background:
A few studies have suggested that lipid-lowering drugs may have anti-arrhythmic effects in patients with coronary artery disease.
Methods:
Patients receiving an ICD (n = 654; U.S. centers only) in the MADIT-II study were categorized by the percentage of days each patient received statins during follow-up (90% to 100%, n = 386; 11% to 89%, n = 116; and 0% to 10%, n = 152). The Kaplan-Meier method with significance testing by the log-rank statistic and time-dependent proportional hazards regression analysis were used to evaluate the effect of statin use on the probability of ICD therapy for the combined end point VT/VF or cardiac death and for the end point VT/VF.
Results:
The cumulative rate of ICD therapy for VT/VF or cardiac death, whichever occurred first, was significantly reduced in those with > or =90% statin usage compared to those with lower statin usage (p = 0.01). The time-dependent statin:no statin therapy hazard ratio was 0.65 (p < 0.01) for the end point of VT/VF or cardiac death and 0.72 (p = 0.046) for VT/VF after adjusting for relevant covariates.
Conclusions:
Statin use in patients with an ICD was associated with a reduction in the risk of cardiac death or VT/VF, whichever occurred first, and was associated with a reduction in VT/VF episodes. These findings suggest that statins have anti-arrhythmic properties.
Related Concept Videos
01:25Dysrhythmias VI: Management of Dysrhythmias
01:29Cardiomyopathy V: Interprofessional Care
01:25ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias